Biomarkers – Products

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples.

Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.

Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease.

To accelerate the discovery of new cancer biomarkers and new insights into the genetics of treatment-resistant tumors, it is crucial to gain a deeper understanding of the genomic and epigenomic variations in cancer.

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma.

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.

This app note highlights a highly sensitive method developed for the detection of GalSPH and GluSPH in CSF.